Grant: Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
University of British Columbia
$10,000.00
Immunometabolism in diabetes: harnessing metabolic crosstalk between islets and immune cells for therapy
FY 2020-21
Summary
Type 1 diabetes (T1D) is an autoimmune disease that occurs when the immune system mistakenly kills the cells in the pancreas that produce the hormone, insulin. A true cure for T1D requires the immune system to be re-set so it no longer attacks the pancreas, and the insulin-producing cells to be replaced or regenerated. We have assembled a unique team of experts in immune cell and insulin-producing cell biology and diabetes, to study why the immune system becomes over-activated and kills insulin-producing beta cells and causes T1D. We will focus on a growing area of research known as immunometabolism, which is the study of how metabolic pathways inside cells affect their ability to divide and function. We hypothesize that beta cells may create a metabolic environment that promotes autoimmunity. We will use samples from mice or people that are healthy or have T1D to study how cellular metabolic pathways might be altered in T1D. We will also investigate how factors made by the beta cells themselves might influence the metabolic activity of immune cells. This work will lead us to discover new ways that we could intervene to inhibit immune cell killing. We also plan to use new genetic engineering approaches to manipulate the ability of immune cells to respond to islet-derived factors and/or change the activity of specific metabolic pathways. The outcome of this work is that we will gain a better understanding of how altered metabolism influences autoimmunity and be able to design new ways to manipulate key metabolic processes to prevent or slow T1D progression.
Department
Program
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
446709
Name
Verchere Bruce C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Team Grant: Diabetes Mechanisms and Translational Solutions - LOI
Projecttitle
Immunometabolism in diabetes: harnessing metabolic crosstalk between islets and immune cells for therapy
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$10,000
Cihrequipment2
$0
Programname2
Team Grant: DM/TS - CIHR-JDRF - ß-cell and Pancreatic Islet Physiology - LOI
Keyworddelim
Immunometabolism; Immunomodulation; Insulin; Islet; Macrophages; Metabolomics; Sex Differences; T Cells; T Regulatory Cells; Type 1 Diabetes
Abstract
Type 1 diabetes (T1D) is an autoimmune disease that occurs when the immune system mistakenly kills the cells in the pancreas that produce the hormone, insulin. A true cure for T1D requires the immune system to be re-set so it no longer attacks the pancreas, and the insulin-producing cells to be replaced or regenerated. We have assembled a unique team of experts in immune cell and insulin-producing cell biology and diabetes, to study why the immune system becomes over-activated and kills insulin-producing beta cells and causes T1D. We will focus on a growing area of research known as immunometabolism, which is the study of how metabolic pathways inside cells affect their ability to divide and function. We hypothesize that beta cells may create a metabolic environment that promotes autoimmunity. We will use samples from mice or people that are healthy or have T1D to study how cellular metabolic pathways might be altered in T1D. We will also investigate how factors made by the beta cells themselves might influence the metabolic activity of immune cells. This work will lead us to discover new ways that we could intervene to inhibit immune cell killing. We also plan to use new genetic engineering approaches to manipulate the ability of immune cells to respond to islet-derived factors and/or change the activity of specific metabolic pathways. The outcome of this work is that we will gain a better understanding of how altered metabolism influences autoimmunity and be able to design new ways to manipulate key metabolic processes to prevent or slow T1D progression.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Verchere, Bruce C; Klein Geltink, Ramon; Levings, Megan K; Santamaria, Pere; Tsai, Sue Y
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $10,000~ $0~